Filgrastim Biosimilars Market Size Forecasted To Achieve $1.21 Billion By 2029 With Steady Growth

The Filgrastim Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Filgrastim Biosimilars Market Size and Projected Growth Rate?
The market size for filgrastim biosimilars has experienced significant expansion in the past few years. The market is projected to increase from $0.92 billion in 2024 to $0.98 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this growth during the historic period include emerging market development, the rise in patent expirations, initiatives by the government, enhanced healthcare spending, the affordability of biosimilars, a robust drug pipeline, and an increase in biopharmaceutical R&D spending.

In the upcoming years, the filgrastim biosimilars market is anticipated to witness robust expansion, eventually reaching a market value of $1.21 billion in 2029, with a compound annual growth rate (CAGR) of 5.4%. This imminent growth during the forecast period can be credited to the escalating elderly population and enhanced health care accessibility. Crucial trends expected throughout this period consist of concentrated investments in research and development for the creation of innovative and effective biosimilars, production of biosimilars specifically for neutropenia treatment to boost income, and increasing emphasis on mergers and acquisitions as a part of their growth strategy.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4016

What Are the Major Segments in the Filgrastim Biosimilars Market?
The filgrastim biosimilars market covered in this report is segmented -

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:
1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing
2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Are The Driving Filgrastim Biosimilars Market Evolution?
The continuous rise in the incidence of neutropenia is anticipated to enhance the growth of the filgrastim biosimilar market. The term neutropenia is coined for a situation where the body lacks sufficient neutrophils, a type of white blood cell that aids in battling infections. Filgrastim biosimilars function by encouraging the production of neutrophils in the bone marrow, thereby increasing the count of neutrophils that assist in fighting infections. For example, as per the information in August 2022 from the National Center for Biotechnology Information, a U.S. based database dedicated to biomedical literature, the neutropenia incidence was observed to be 0.38% among Mexican-Americans, 0.79% among whites and 4.5% among black participants. Hence, the escalating incidence of neutropenia is acting as a catalyst for the growth of the filgrastim biosimilar market.

Which Firms Dominate The Filgrastim Biosimilars Market Segments?
Major companies operating in the filgrastim biosimilars market include Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Fuji Pharma, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratórios

What Trends Are Expected to Dominate the Filgrastim Biosimilars Market in the Next 5 Years?
Key players in the filgrastim biosimilar sector are focusing on creating groundbreaking products using modern technologies such as recombinant DNA technology for biosimilar production. This technique involves the modification of the host organism's DNA by integrating a foreign sequence into it. For example, in May 2023, FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen's NEULASTA, was introduced in the United States by the US-based Amneal Pharmaceuticals. This product is deployed for the treatment and prevention of febrile neutropenia; it aids in the growth and specialisation of neutrophils emanating from their precursor cells, facilitating their maturation, and reinforcing the effectiveness and longevity of fully grown neutrophils. This results in dosage-dependent increases in neutrophil counts. The introduction of Fylnetra paves the way for the next series of cost-effective medicines and enhances access for patients, providers, and payors.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Which Is The Largest Region In The Filgrastim Biosimilars Market?
North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Filgrastim Biosimilars Market?
2. What is the CAGR expected in the Filgrastim Biosimilars Market?
3. What Are the Key Innovations Transforming the Filgrastim Biosimilars Industry?
4. Which Region Is Leading the Filgrastim Biosimilars Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.